Categories

AstraZeneca announces additional approval for ENHERTU® (fam-trastuzumab deruxtecan-nxki)

AstraZeneca recently announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki) is now approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti–HER2-based regimen either: in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.1 ENHERTU has Boxed […]

Read More No Comments

Register Now for OSCO’s “Best of” San Antonio Breast Cancer Symposium® Virtual Symposium to be held March 19, 2022

The Oklahoma Society of Clinical Oncology, Inc. would like to invite you to attend our 2022 Spring meeting. Join your colleagues to hear highlights from this state-of-the art symposium on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease. The “Best of” SABCS is an officially licensed program of the San Antonio […]

Read More No Comments

Additional FDA approval for KEYTRUDA® announced

Merck announces that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.  •  PD-L1 diagnostic testing is not required prior to initiating treatment with KEYTRUDA in these patients.  Before prescribing KEYTRUDA® (pembrolizumab), please read the Prescribing Information. The Medication […]

Read More No Comments

KEYTRUDA® (pembrolizumab) indicated for adjuvant treatment of Renal Cell Carcinoma

KEYTRUDA® (pembrolizumab) is indicated for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. SELECTED SAFETY INFORMATION Severe and Fatal Immune-Mediated Adverse Reactions •  KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to […]

Read More No Comments

Oncopeptides withdraws Pepaxto® in US, scale down organization and focus on R&D

October 22, 2021     Subject: Voluntary withdrawal of PEPAXTO® (melphalan flufenamide) for the treatment of relapsed or refractory multiple myeloma   Dear Healthcare Provider:  This letter is to inform you about important information regarding PEPAXTO in the United States.  On October 22, 2021, Oncopeptides announced the decision to voluntarily withdraw the US accelerated approval for […]

Read More No Comments

Pfizer offers COVID-19 Vaccine Training Sessions

Pfizer Vaccines US Medical Affairs will be hosting Immunization Site Training Sessions for All Providers on the Storage, Handling, & Administration for Current & Potential New Formulations of our COVID-19 vaccine (with our partner BioNTech). These sessions will be updated to reflect new information and changes that evolve.  Such updates will be identified at the start of each session and further explained […]

Read More No Comments

New life-changing survival data for women with HR+/HER2- metastatic breast cancer

Novartis is pleased to share new study results for KISQALI® (ribociclib), which now include overall survival (OS) data that no other CDK 4/6 inhibitor has yet reported: statistically significant OS in in first-line postmenopausal patients with an aromatase inhibitor.1 MONALEESA-2 was a dedicated first-line trial of KISQALI + letrozole vs placebo + letrozole in postmenopausal patients […]

Read More No Comments

U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia

BeiGene Ltd. Announces a new approval for BRUKINSA (zanubrutinib) in Waldenström’s macroglobulinaemia, including the updated Prescribing Information. For more information: Download BRUKINSA Full Prescribing Information Download BRUKINSA Patient Information BRUKINSA WEBSITE

Read More No Comments

Clinical Trial Support Center Available to Connect Patients with Blood Cancer to Clinical Trials

ASH and The Leukemia & Lymphoma Society (LLS) Clinical Trial Support Center (CTSC) have collaborated to enhance access to LLS’s free service providing clinical trials navigation and support to health care professionals, and patients with blood cancer and their families. ASH member physicians and their care teams, along with patients and caregivers, receive one-on-one support […]

Read More No Comments

New ASCO-COA Oncology Medical Home Standards Set High Bar, Offers Roadmap for Comprehensive High-Quality, Patient-Centered Cancer Care Delivery 

On July 13, the American Society of Clinical Oncology (ASCO) and the Community Oncology Alliance (COA) jointly released new Oncology Medical Home (OMH) standards to provide a comprehensive roadmap for oncology practices to deliver high-quality, evidence based cancer care. By releasing the new standards, ASCO and COA seek to achieve a broad consensus among all […]

Read More No Comments